ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

ClinicalTrials.gov ID: NCT00635817

Public ClinicalTrials.gov record NCT00635817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty

Study identification

NCT ID
NCT00635817
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Abbott
Industry
Enrollment
84 participants

Conditions and interventions

Interventions

  • Leuprolide acetate 11.25 mg Drug
  • Leuprolide acetate 30 mg Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2008
Primary completion
Dec 31, 2009
Completion
May 31, 2010
Last update posted
Nov 1, 2011

2008 – 2010

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Site Reference ID/Investigator# 8765 Birmingham Alabama 35233
Site Reference ID/Investigator# 11522 Long Beach California 90806
Site Reference ID/Investigator# 8756 Los Angeles California 90027
Site Reference ID/Investigator# 8755 San Diego California 92123
Site Reference ID/Investigator# 8761 San Diego California 92123
Site Reference ID/Investigator# 8772 Stanford California 94305-5208
Site Reference ID/Investigator# 8749 Greenwood Village Colorado 80111
Site Reference ID/Investigator# 8771 Gainesville Florida 32608
Site Reference ID/Investigator# 8764 Jacksonville Florida 32207
Site Reference ID/Investigator# 17621 Pensacola Florida 32504
Site Reference ID/Investigator# 8752 Indianapolis Indiana 46202
Site Reference ID/Investigator# 8766 Shreveport Louisiana 71103
Site Reference ID/Investigator# 8768 Minneapolis Minnesota 55455
Site Reference ID/Investigator# 17341 Saint Paul Minnesota 55102
Site Reference ID/Investigator# 8759 Kansas City Missouri 64108
Site Reference ID/Investigator# 8750 Oklahoma City Oklahoma 73104
Site Reference ID/Investigator# 8760 Tulsa Oklahoma 74135
Site Reference ID/Investigator# 8763 Hershey Pennsylvania 17033
Site Reference ID/Investigator# 8754 Salt Lake City Utah 84108
Site Reference ID/Investigator# 8762 Seattle Washington 98104
Site Reference ID/Investigator# 8753 Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00635817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2011 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00635817 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →